

# Public Affairs Briefing



NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE  
Appraisal consultation document  
Dronedarone for the treatment of non-permanent atrial fibrillation

## Comments from The Stroke Association

The Stroke Association welcomes the opportunity to comment on the new NICE appraisal consultation document: Dronedarone for the treatment of non-permanent atrial fibrillation (AF).

We welcome the revised treatment recommendations in the document as this represents a step forward for the treatment of a subgroup of AF patients who are currently difficult to treat, as we understand that this new drug may both reduce the symptoms of AF and improve outcomes in respect of reduced death from stroke.

We believe the adoption of these revised guidelines will expand the limited number of treatment options currently available to AF patients and could bring significant quality of life improvements for those patients who find existing anti-arrhythmic drugs ineffective or cannot tolerate the drug they are prescribed.

21<sup>st</sup> April 2010

The Stroke Association

